NeoGenomics Announces Senior Leadership Promotions
18 4월 2024 - 8:05PM
Business Wire
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, today announced two promotions within its
senior leadership team, effective immediately.
Warren Stone has been promoted to Chief Commercial Officer and
will lead NeoGenomics’ clinical and pharma services commercial
teams. Stone will be responsible for sales, marketing, pharma
project management, commercial enablement, scientific affairs, and
support functions.
Melody Harris has been promoted to Chief Operations Officer and
President, Informatics. In this expanded role, Harris will oversee
data-oriented teams and manage all enterprise operations.
“Warren and Melody have shown exceptional leadership and
performance in their respective roles," said Chris Smith, CEO of
NeoGenomics. “As we enter our next phase of growth, these senior
leadership appointments should drive operational efficiencies,
strengthen commercial synergies, and accelerate innovation through
R&D. We believe their extensive experience will enhance the
operating structure of the organization, thereby improving our
service to clinicians and patients.”
Stone joined NeoGenomics in 2022 as President of Clinical
Services. He has played a leading role in optimizing NeoGenomics’
salesforce and successfully implementing its commercial strategy
and digital transformation of systems and tools. Prior to
NeoGenomics, Stone served as President of Americas at Ortho
Clinical Diagnostics and Senior Vice President, Life Sciences
Division for MilliporeSigma. He holds an MBA from Suffolk
University.
Harris joined NeoGenomics in 2022 as President of Enterprise
Operations. She has led the company through a laboratory
transformation including improvements in turnaround time and
currently manages the consolidation of several laboratory
information management systems (LIMS) into a single system. Prior
to NeoGenomics, Harris served as President and Chief Operating
Officer at SomaLogic and held several executive positions at
Qualcomm Life’s digital health subsidiary and at HealthyCircles, a
healthcare web platform. Harris holds a BA, cum laude, in Political
Science from the University of Denver and a JD, cum laude, from
Harvard Law School.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus in the world for physicians to help
them diagnose and treat cancer. The Company's Pharma Services
Division serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, Fla., NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
Forward-Looking Statements
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “plan,” “could,” “would,”
“may,” “will,” “believe,” “estimate,” “forecast,” “goal,”
“project,” “guidance,” “plan,” “potential” and other words of
similar meaning, although not all forward-looking statements
include these words. This press release includes forward-looking
statements. These forward-looking statements address various
matters, including statements regarding improving operational
efficiency, returning to profitable growth and its ongoing
executive recruitment process. Each forward-looking statement
contained in this press release is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, the Company's ability to
identify and implement appropriate financial and operational
initiatives to improve performance, to identify and recruit
executive candidates, to continue gaining new customers, offer new
types of tests, integrate its acquisitions and otherwise implement
its business plan, and the risks identified under the heading "Risk
Factors" contained in the Company's Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and the Company's other filings with
the Securities and Exchange Commission.
We caution investors not to place undue reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this document (unless another date is
indicated), and we undertake no obligation to update or revise any
of these statements. Our business is subject to substantial risks
and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240418774066/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
NeoGenomics (NASDAQ:NEO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024